Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

https://www.soho2019.com/

 

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

BCL-2 Inhibition in AML: High Effectiveness of Combination Therapy - Overview of Trials Combining Venetoclax and Targeted Agents (IDH, FLT3, MDM2 Inhibitors)

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Marina Konopleva
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Marina Konopleva
134 views
November 5, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
Breakfast With The Expert
16:04

Optimizing Care for the Older Adolescent and Young Adult: Health Car…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

N. Boissel

15 views
14:32

ALL Therapy for the Young Adults: Adoption of Pediatric Regimen, MRD…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

W. Stock

15 views
39:21

BCL-2 Inhibition in AML: High Effectiveness of Combination Therapy -…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

M. Konopleva

134 views
12:03

Histology of the Marginal Zone Lymphoma

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

E. Zucca

42 views
21:31

Marginal Zone Lymphoma: Role of PET, Antibiotic Therapy in Non-GI MA…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

E. Zucca

47 views